Fundamentals - AlphaKey Financial

Stock Fundamentals

Company Information

▼

Company Name

Biohaven Pharmaceutical Holding Co Ltd

Sector

Healthcare

Industry

Biotechnology

Exchange

NYSE

ISIN: VGG111961055

CIK: 0001689813

Currency: USD

Full Time Employees: 256

Phone: 203 404 0410

Website: https://www.biohaven.com

Fiscal Year End: December

IPO Date: Sep 23, 2022

Description:

Biohaven Ltd. discovers, develops, and commercializes therapies for immunology, neuroscience, and oncology worldwide. The company develops troriluzole, which is in Phase 3 trial for the treatment of neurological and neuropsychiatric illnesses; taldefgrobep alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 3 clinical trial for the treatment of focal and generalized epilepsy, and major depressive disorder; BHV-2100 that is in Phase 2 clinical trial for the treatment of migraines and pain disorders; BHV-1510, which is in Phase ½ trial that targets advanced or metastatic epithelial tumors; and BHV-8000, a product candidate that completed Phase 1 clinical trial for the treatment of Alzheimer's and Parkinson's disease, and multiple sclerosis, as well as prevention of amyloid-related imaging abnormalities. It is also developing BHV-1300, which in Phase 1 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 1 trial for IgA nephropathy; BHV-1100, which is in Phase 1 trial for multiple myeloma patients; BHV-1600, which is in Phase 1 trial for the treatment of peripartum cardiomyopathy; BHV-1310 that is in preclinical trial for the treatment of generalized myasthenia gravis and other acute exacerbations or flares; BHV-1530, which is in preclinical trial to treat urothelial cancer; BHV-1500 that is in preclinical trial for Hodgkin's lymphoma; and BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors. The company has strategic partnerships with Merus N.V., GeneQuantum Healthcare (Suzhou) Co. Ltd., Aimed Bio, Inc., Yale University, Katholieke Universiteit Leuven, Bristol Meyers Squibb, and Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven Ltd. was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Address:

215 Church Street, New Haven, CT, United States, 06510

Directors & Officers

▼

Name	Title	Year Born
Dr. Vladimir Coric M.D.	Chairman & CEO	1971
Mr. Matthew Buten	Chief Financial Officer	1961
Dr. Bruce D. Car DACVP, Ph.D.	Chief Scientific Officer	1962
Ms. Kimberly Gentile	Senior Vice President of Clinical Operations	1966
Ms. Deb Young	Senior Director of Regulatory Affairs & Operations	NA
Mr. George C. Clark CPA	VP & Chief Accounting Officer	1985
Ms. Jennifer Porcelli	Vice President of Investor Relations	NA
Mr. Warren Volles J.D.	General Counsel & Chief Legal Officer	NA
Mr. Clifford Bechtold M.S.	President, GM of Biohaven Ireland & Chief Compliance Officer	NA
Mr. John Tilton	Chief Commercial Officer of Rare Diseases	1968

Institutional Holders

▼

Holder Name	Shares	Date Reported	% Out	Value	% Change
Suvretta Capital Management, LLC	10.29M	Dec 31, 2025	7.75%	$2.38	83.03%
BlackRock Inc	7.87M	Sep 30, 2025	5.93%	$0.00	4.51%
HHG PLC	6.77M	Sep 30, 2025	5.10%	$0.05	34.01%
Stifel Financial Corp	6.61M	Sep 30, 2025	4.98%	$0.09	0.06%
Vanguard Group Inc	4.40M	Dec 31, 2025	3.31%	$0.00	52.89%
State Street Corp	4.26M	Sep 30, 2025	3.21%	$0.00	20.35%
D. E. Shaw & Co LP	2.69M	Dec 31, 2025	2.03%	$0.02	112.68%
FMR Inc	2.68M	Dec 31, 2025	2.02%	$0.00	10.52%
JPMorgan Chase & Co	2.67M	Sep 30, 2025	2.01%	$0.00	3.84%
BNP Paribas Arbitrage, SA	2.09M	Dec 31, 2025	1.58%	$0.01	233.08%
Geode Capital Management, LLC	2.06M	Sep 30, 2025	1.55%	$0.00	1.44%
T. Rowe Price Associates, Inc.	2.01M	Sep 30, 2025	1.51%	$0.00	-36.63%
Schonfeld Strategic Advisors LLC	1.61M	Dec 31, 2025	1.21%	$0.08	3,829.90%
Balyasny Asset Management LLC	1.59M	Dec 31, 2025	1.20%	$0.02	317.74%
The Goldman Sachs Group Inc	1.58M	Sep 30, 2025	1.19%	$0.00	61.07%
VOLORIDGE INVESTMENT MANAGEMENT, LLC	1.32M	Dec 31, 2025	0.99%	$0.05	758.37%
Qube Research & Technologies	1.27M	Sep 30, 2025	0.95%	$0.02	834.43%
Two Sigma Investments LLC	1.26M	Dec 31, 2025	0.95%	$0.02	57.46%
MYDA Advisors LLC	1.25M	Dec 31, 2025	0.94%	$2.69	1,566.67%
Schmeidler A R & CO Inc	1.24M	Dec 31, 2025	0.93%	$0.82	12.43%

Shares Statistics

▼

Shares Outstanding: 132.69M

Shares Float: 84.69M

% Insiders: 954.80%

% Institutions: 8,985.30%

Short % Float: 17.77%

🏆 Top 10 Institutional Holders

▼

Rank	Holder Name	Shares Held	% of Shares	Change	Date Reported
1	Suvretta Capital Management, LLC	10.29M	7.75%	▲ 83.03%	Dec 31, 2025
2	BlackRock Inc	7.87M	5.93%	▲ 4.51%	Sep 30, 2025
3	HHG PLC	6.77M	5.10%	▲ 34.01%	Sep 30, 2025
4	Stifel Financial Corp	6.61M	4.98%	▲ 0.06%	Sep 30, 2025
5	Vanguard Group Inc	4.40M	3.31%	▲ 52.89%	Dec 31, 2025
6	State Street Corp	4.26M	3.21%	▲ 20.35%	Sep 30, 2025
7	D. E. Shaw & Co LP	2.69M	2.03%	▲ 112.68%	Dec 31, 2025
8	FMR Inc	2.68M	2.02%	▲ 10.52%	Dec 31, 2025
9	JPMorgan Chase & Co	2.67M	2.01%	▲ 3.84%	Sep 30, 2025
10	BNP Paribas Arbitrage, SA	2.09M	1.58%	▲ 233.08%	Dec 31, 2025

Valuation Metrics

▼

Enterprise Value: $1.58B

Trailing P/E: 0.00

Forward P/E: 0.00

Financial Highlights

▼

Market Cap: $1.53B

EBITDA: $-771.87M

Book Value: $-0.16

Earnings/Share: $-7.52

Profit Margin: 0.00%

Operating Margin: 0.00%

ROA (TTM): -106.25%

ROE (TTM): -522.08%

Revenue (TTM): $0.00

Revenue/Share (TTM): $0.00

Earnings Growth (YOY): 0.00%

Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios (Yearly)

▼

Financial Ratios (Quarterly)

▼

Earnings History

▼

Date	EPS Actual	EPS Estimate	Difference	Surprise %
Mar 31, 2026	0.00	-1.04	N/A	10,000.00%
Dec 31, 2025	0.00	-1.18	N/A	10,000.00%
Sep 30, 2025	-1.64	-1.88	N/A	1,276.60%
Jun 30, 2025	-1.94	-1.94	N/A	0.00%
Mar 31, 2025	-2.17	-1.70	N/A	-2,764.71%
Dec 31, 2024	-1.71	-1.60	N/A	-687.50%
Sep 30, 2024	-1.74	-1.70	N/A	-235.29%
Jun 30, 2024	-3.50	-1.78	N/A	-9,662.92%
Mar 31, 2024	-2.20	-1.57	N/A	-4,012.74%
Dec 31, 2023	-1.81	-1.41	N/A	-2,836.88%
Sep 30, 2023	-1.50	-1.34	N/A	-1,194.03%
Jun 30, 2023	-1.32	-1.21	N/A	-909.09%
Mar 31, 2023	-1.03	-1.41	N/A	2,695.04%
Dec 31, 2022	-3.32	-1.22	N/A	-17,213.11%
Sep 30, 2022	-1.75	-2.34	N/A	2,521.37%
Jun 30, 2022	-6.21	-2.58	N/A	-14,069.77%
Mar 31, 2022	-2.97	-2.53	N/A	-1,739.13%
Dec 31, 2021	-3.01	-2.04	N/A	-4,754.90%
Sep 30, 2021	-2.63	-2.40	N/A	-958.33%
Jun 30, 2021	-3.23	-2.72	N/A	-1,875.00%
Mar 31, 2021	-4.21	-2.82	N/A	-4,929.08%
Dec 31, 2020	-3.62	-2.97	N/A	-2,188.55%
Sep 30, 2020	-3.27	-2.89	N/A	-1,314.88%
Jun 30, 2020	-3.08	-2.61	N/A	-1,800.77%
Mar 31, 2020	-3.07	-2.34	N/A	-3,119.66%
Dec 31, 2019	-2.85	-1.87	N/A	-5,240.64%
Sep 30, 2019	-2.04	-1.57	N/A	-2,993.63%
Jun 30, 2019	-4.67	-1.92	N/A	-14,322.92%
Mar 31, 2019	-1.41	-1.48	N/A	472.97%
Dec 31, 2018	-1.34	-1.21	N/A	-1,074.38%
Sep 30, 2018	-1.53	-1.07	N/A	-4,299.07%
Jun 30, 2018	-1.01	-1.18	N/A	1,440.68%
Mar 31, 2018	-2.32	-1.14	N/A	-10,350.88%
Dec 31, 2017	-0.75	-1.20	N/A	3,750.00%
Sep 30, 2017	-1.19	-1.10	N/A	-818.18%
Jun 30, 2017	-1.78	-0.61	N/A	-19,180.33%
Mar 31, 2017	-1.74	-0.79	N/A	-12,025.32%
Dec 31, 2016	0.00	0.00	N/A	N/A
Dec 31, 1990	-4.67	0.00	N/A	N/A

Balance Sheet (Yearly)

▼

Date	Cash	Total Debt	Total Assets	Total Liabilities	Total Equity
2024-12-31	$99.13M	$N/A	$615.11M	$191.67M	$423.44M
2023-12-31	$248.40M	$N/A	$513.21M	$85.24M	$427.98M
2022-12-31	$204.88M	$N/A	$661.78M	$123.01M	$538.77M
2021-12-31	$76.06M	$N/A	$142.06M	$47.37M	$34.69M
2020-12-31	$82.51M	$N/A	$111.50M	$34.72M	$16.78M
2019-12-31	$316.73M	$N/A	$344.26M	$351.69M	$-7.42M
2018-12-31	$264.25M	$N/A	$290.01M	$139.09M	$150.92M
2017-12-31	$131.47M	$N/A	$146.89M	$14.92M	$131.97M

Financial Ratios

▼

Date	Current Ratio	Debt/Equity	Debt/Assets	Interest Coverage	Debt/EBITDA
2024-12-31	3.49x	0.01x	0.31x	N/A	0.00x
2023-12-31	7.98x	0.01x	0.17x	N/A	-0.01x
2022-12-31	6.52x	0.01x	0.19x	-409.76x	-0.01x
2021-12-31	2.26x	18.08x	0.33x	-5.27x	-2.88x
2020-12-31	3.00x	0.04x	0.31x	N/A	-0.01x
2019-12-31	4.96x	0.00x	1.02x	-37.69x	0.00x
2018-12-31	13.94x	0.00x	0.48x	N/A	N/A
2017-12-31	14.49x	0.00x	0.10x	N/A	0.00x

Insider Trading

Date	Insider Name	Title	Transaction Type	Shares	Price	Value
Nov 17, 2025	George C Clark	N/A	Purchase	17.00K	$8.52	$144.84K
Nov 13, 2025	Gregory Bailey	N/A	Purchase	400.00K	$7.50	$3.00M
Nov 13, 2025	John W Childs	N/A	Purchase	3.33M	$7.50	$25.00M
Nov 13, 2025	Vlad Coric	N/A	Purchase	666.67K	$7.50	$5.00M
Mar 04, 2025	John W Childs	N/A	Purchase	32.70K	$30.47	$996.37K

📦 Raw API Data (JSON Explorer)

▼

Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.

Stock Fundamentals

Company Information

Directors & Officers

Institutional Holders

Shares Statistics

🏆 Top 10 Institutional Holders

Valuation Metrics

Financial Highlights

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios (Yearly)

Financial Ratios (Quarterly)

Earnings History

Balance Sheet (Yearly)

Financial Ratios

Insider Trading

📦 Raw API Data (JSON Explorer)

Watchlist

Assistant